TargED Biopharmaceuticals (TargED), a private biotechnology company focused on developing improved treatments for thrombotic diseases, has raised Series A financing of EUR39 million to accelerate development of its lead compound, Microlyse.

The financing was led by an international syndicate with equal contributions from Andera Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures, and joined by existing investors FIRST (Managed by BioGeneration Ventures), Curie Capital and Utrecht Health Seed Fund. 

TargED will focus development on two initial indications: acquired Thrombotic Thrombocytopenia Purpura (aTTP) and Acute Ischemic Stroke (AIS).